Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home

This is a multi-center, single-arm double-blinded prospective clinical study to determine the optimal frequency of home B-type natriuretic peptide (BNP) testing and the changes in BNP concentrations that correlate with clinical heart failure (HF) decompensation and related adverse clinical outcomes in at-risk HF patients. Approximately 200 subjects will be enrolled.

Inclusion criteria

• Adults (18 years of age or older);
• Admitted to the hospital or observation unit with a diagnosis of decompensated HF for which treatment will be administered;
• Blood BNP level measurement > 400 pg/mL documented during admission; If NT-proBNP is used routinely in the laboratory at a clinical site rather than BNP, then blood NT-proBNP level measurement > 1,600 pg/mL documented during admission.
• Successfully trained on how to perform a fingerstick and to use the Triage touch.
• Either the subject or their care provider is fluent in reading and writing English

Exclusion criteria

• Unwilling or unable to provide written informed consent;
• Acute coronary syndrome (ACS) that is concomitant with the diagnosis of decompensated HF and for which treatment will be provided.

A history of ACS is not reason for exclusion if it is not concomitant with the present decompensated HF for which admission is being made. Small elevations in cardiac troponin that are considered by the treating physician to be associated with myocardial injury due to the acute decompensated HF and not due to a concomitant ACS or myocardial infarction are not a basis for exclusion.

• Previous cardiac transplantation - or cardiac transplantation anticipated within 3 months;
• Current or planned use of a left ventricular assist device (LVAD), use of outpatient intravenous inotropic HF therapy, major surgical procedure or percutaneous coronary intervention within 3 months;
• Life expectancy less than 3 months due to causes other than HF or cardiovascular disease (e.g., cancer);
• End stage renal disease;
• Prisoner or other institutionalized or vulnerable individual;
• Residence in regions where either transmission of Triage Touch data or a home visit on day 5 is not possible.
• Dementia, tremors or other impediments to performing daily home BNP testing via fingerstick.
• Deemed by the Investigator not to be likely to comply with study-mandated procedures or instructions.